UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net income	$ 16,635	$ 16,473	$ 14,788
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	623	612	636
Amortization	5,692	6,417	6,645
Provision for losses on accounts receivable	(33)	30	24
Amortization of operating lease assets	53	53	3
Deferred income taxes	(693)	(401)	(92)
Stock-based compensation expense	225	183	166
Tax benefit attributable to exercise of stock options	12	6	39
Accounts receivable	2,270	(511)	(1,088)
Other receivables	0	(14)	(42)
Inventories	(670)	(2,353)	(485)
Prepaid expenses and other current assets	45	(64)	(81)
Accounts payable	(456)	464	(23)
Accrued expenses	(1,422)	252	713
Net cash provided by operating activities	22,281	21,147	21,203
Cash flows from investing activities
Property and equipment	(639)	(809)	(552)
Intangible assets	0	(9)	0
Net cash (used in) investing activities	(639)	(818)	(552)
Cash flows from financing activities
Proceeds from issuance of common stock - options	117	174	560
Common stock purchased and retired	0	(2,495)	0
Dividends paid	(4,282)	(3,163)	(11,465)
Net cash (used in) financing activities	(4,165)	(5,484)	(10,905)
Effect of exchange rate changes on cash	339	(767)	(362)
Net increase in cash and cash equivalents	17,816	14,078	9,384
Cash at beginning of year	75,052	60,974	51,590
Cash at end of year	92,868	75,052	60,974
Cash paid during the year for income taxes	4,827	4,970	4,617
Cash paid during the year for interest	$ 0	$ 0	$ 0